Clinical Trial Update: Pulsed Dose Chemotherapy Plus Pembrolizumab in Recurrent/Metastatic HNSCC [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating pulsed-dose chemotherapy in combination with pembrolizumab for recurrent/metastatic head and neck squamous cell carcinoma…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Pembrolizumab (pembrolizumab)
• Pulsed-dose chemotherapy

Snippet

Sponsor: Dan Zandberg | Conditions: Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) | Phase 2 | Status: RECRUITING